Becton, Dickinson Earnings Call: Growth Amid Tariff Drag

Becton, Dickinson and Co ((BDX)) has held its Q1 earnings call. Read on for the main highlights of the call.

Becton, Dickinson and Co.’s latest earnings call struck a cautiously upbeat tone, pairing solid operational execution and strong performance in core growth platforms with clear acknowledgment of near-term pressures. Management emphasized productivity gains, cash generation, and strategic capital deployment, even as tariffs, China pricing, and vaccine softness weighed on margins and overall growth.

Revenue Stability and NewCo Growth

BD reported Q1 revenue of $5.3 billion, up just 0.4% year over year as legacy Life Sciences and other headwinds offset underlying strength. The new post-transaction Becton, Dickinson and Company portfolio showed healthier momentum, growing 2.5% with roughly 90% of NewCo delivering mid‑single‑digit gains.

Growth Engines in High-Value Platforms

Key growth platforms continued to outperform, with double‑digit gains in biologic drug delivery, PureWick, advanced tissue regeneration, and pharmacy automation, plus high single‑digit growth in advanced patient monitoring. The company now has contracts covering more than 80 GLP‑1 novel and biosimilar molecules, underscoring its leverage to expanding obesity and diabetes markets.

Margins and EPS Beat Internal Expectations

Adjusted EPS of $2.91 declined 15.2% from a strong prior year, yet still beat management’s expectations thanks to revenue mix and tight execution. Adjusted gross margin came in at 53.4%, also ahead of internal plans, as productivity initiatives helped offset significant external cost pressures.

Strategic Waters Transaction and Cash Inflow

BD completed the Reverse Morris Trust combination of its Life Sciences business with Waters, crystallizing value and simplifying the portfolio. The company received a $4.0 billion cash distribution from the deal, creating meaningful firepower for both shareholder returns and balance sheet strengthening.

Shareholder Returns and Deleveraging Roadmap

In Q1, BD returned roughly $550 million to investors through dividends and $250 million of share repurchases. Management further committed to a $2.0 billion accelerated share repurchase and $2.0 billion of debt repayment from the Waters proceeds, aiming to move net leverage from 2.9x toward its 2.5x long‑term target.

Productivity Gains and Cost-Out Progress

The BD Excellence program delivered an 8% productivity improvement in the quarter, directly supporting margins and profitability. The company has already executed $150 million, or 75%, of its planned $200 million cost‑out program, positioning it to better absorb inflation and tariff impacts.

Improved Free Cash Flow and Conversion

Free cash flow reached $548 million in Q1, reflecting stronger cash generation despite modest top‑line growth. Free cash flow conversion improved to 66% from 59% a year ago, driven by better working capital management and capital efficiency, bolstering BD’s flexibility for investment and capital returns.

Commercial Momentum and New Launches

Commercial execution remained a bright spot, with the Pyxis Pro launch seeing about 85% of initial orders coming from competitive conversions. Alaris recorded its strongest quarter of competitive wins since relaunch, while new and planned launches like Avitene Flowable, SurgiFor, SurgiFore Pulse, and HemoSphere Stream aim to sustain growth across surgical and monitoring franchises.

Tariffs Weigh on Earnings and Margins

Despite operational wins, tariffs were a major drag, contributing about 170 basis points of gross margin pressure and driving adjusted gross margin down 140 basis points year over year. Adjusted operating margin declined 240 basis points, with management highlighting tariffs as a structural profitability headwind that will persist into future periods.

Muted Top-Line Growth at the Consolidated Level

Headline revenue growth remained subdued at 0.4% as strong NewCo performance was diluted by weaker elements of the portfolio and businesses now treated as discontinued. These legacy and noncore headwinds masked what management characterized as healthier mid‑single‑digit expansion across most of the ongoing company.

China Pricing and Vaccine Demand Headwinds

China’s volume‑based procurement program pressured pricing and order timing in Medical Essentials and Biopharma Systems, crimping growth despite underlying demand. At the same time, lower vaccine demand and weaker research funding weighed on Life Sciences and Vascular Diagnostics, adding another layer of drag in the quarter.

Alaris: Competitive Wins but Near-Term Drag

While Alaris achieved its strongest quarter of competitive conversions since relaunch and gained roughly 100 basis points of share, revenue fell against a tough comparison. Management cautioned that remediation dynamics mean Alaris could be about a 100‑basis‑point headwind in 2026, increasing to around 200 basis points in 2027 as effects fully annualize.

Life Sciences Segment in Decline and Transition

The Life Sciences business, spanning Biosciences and Diagnostic Solutions, declined on U.S. point‑of‑care weakness, challenging comparisons, China pressures, and softer research budgets. With the Waters transaction now closed, BD is treating this segment as discontinued operations, sharpening investor focus on the growth and margin profile of the remaining NewCo.

Balance Sheet Position and Leverage Target

BD ended the quarter with net leverage at 2.9x, sitting above its long‑term target of 2.5x, partly due to the timing of the Waters transaction and capital returns. The planned $2.0 billion of debt repayment using deal proceeds is expected to drive a steady move toward the target, while still allowing for disciplined tuck‑in M&A.

Guidance Framed by Tariffs and Cautious Outlook

Management issued prudent guidance for FY 2026, calling for low single‑digit revenue growth for NewCo, including about a 120 basis‑point FX tailwind, and adjusted EPS of $12.35 to $12.65, roughly 6% growth at the midpoint. The outlook embeds about a 370‑basis‑point tariff headwind and assumes an adjusted operating margin around 25%, interest and other of $600–$620 million, a 16–17% tax rate, and about 282 million shares, with Q2 revenue at roughly 2% growth and EPS of $2.72–$2.82.

BD’s earnings call painted a picture of a business in transition but firmly oriented toward higher‑growth, higher‑margin platforms. While tariffs, China pricing, and product‑specific drags like Alaris and vaccines are real constraints, management’s focus on productivity, disciplined capital deployment, and focused portfolio growth leaves investors with a cautiously constructive story for the coming years.